Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14962804 | 0.92 | HPGD (0.81) | HPGDALDH1A1MAPTSMN1; SMN2ALOX12 | |
| SCHEMBL764569 | 0.85 | HPGD (0.71) | HPGDALDH1A1MAPTSMN1; SMN2ALOX12 | |
| SCHEMBL22854085 | 0.85 | HPGD (0.71) | HPGDALDH1A1MAPTSMN1; SMN2ALOX12 | |
| SCHEMBL14075478 | 0.84 | ALDH1A1 (0.57) | HPGDALDH1A1MAPTSMN1; SMN2ALOX12 | |
| SCHEMBL2091479 | 0.83 | HPGD (0.70) | HPGDALDH1A1MAPTSMN1; SMN2ALOX12 | |
| SCHEMBL2098410 | 0.83 | MTNR1A (0.70) | HPGDALDH1A1MAPTSMN1; SMN2ALOX12 | |
| SCHEMBL16299514 | 0.83 | HPGD (0.69) | HPGDALDH1A1MAPTSMN1; SMN2ALOX12 | |
| SCHEMBL853933 | 0.83 | HPGD (0.70) | HPGDALDH1A1MAPTSMN1; SMN2ALOX12 | |
| SCHEMBL971460 | 0.83 | HPGD (1.00) | HPGDALDH1A1MAPTSMN1; SMN2ALOX12 | |
| SCHEMBL588524 | 0.82 | HPGD (0.86) | HPGDALDH1A1MAPTSMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4381284-B1 | LIGAND-TARGET INTERACTION ANALYSIS BY PHOTOCHEMICALLY INDUCED DYNAMIC NUCLEAR POLARIZATION (PHOTO-CIDNP) ENHANCED NMR SPECTROSCOPY | ETH ZUERICH (CH) | 2025-07-09 | — | — | EP | disclosed |
| US-20240345008-A1 | LIGAND-TARGET INTERACTION ANALYSIS BY PHOTOCHEMICALLY INDUCED DYNAMIC NUCLEAR POLARIZATION (PHOTO-CIDNP) ENHANCED NMR SPECTROSCOPY | ETH ZURICH (CH) | 2024-10-17 | — | — | US | disclosed |
| EP-2332910-B1 | New derivatives of azabicyclo[3.2.0]hept-3-yl, method for preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2013-01-30 | — | — | EP | disclosed |
| US-20120283245-A1 | AZABICYCLO[3.1.0]HEX-2-YL COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2012-11-08 | — | — | US | disclosed |
| EP-2509947-A1 | AZABICYCLO[3.1.0]HEX-2-YL DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier (FR) | 2012-10-17 | — | — | EP | disclosed |
| US-8008337-B2 | Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-08-30 | — | — | US | disclosed |
| WO-2011070251-A1 | NOVEL HEXAHYDROCYCLOPENTA[B]PYRROL DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070252-A1 | AZABICYCLO[3.2.0]HEPT-6-YL DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | LES LABORATOIRES SERVIER (FR) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070253-A1 | AZABICYCLO[3.1.0]HEX-2-YL DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070250-A1 | NOVEL AZABICYCLO[3.2.0]HEPT-3-YL DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2011-06-16 | — | — | WO | disclosed |
| EP-2332910-A1 | New derivatives of azabicyclo[3.2.0]hept-3-yl, method for preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2011-06-15 | — | — | EP | disclosed |
| US-20110136886-A1 | Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-06-09 | — | — | US | disclosed |
| US-7906547-B2 | Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-03-15 | — | — | US | disclosed |
| US-20090312389-A1 | Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-12-17 | — | — | US | disclosed |
| WO-2009150331-A1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2009-12-17 | — | — | WO | disclosed |
| EP-2133333-A1 | New azabicyclic derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2009-12-16 | — | — | EP | disclosed |
| US-7419934-B2 | Reversible thermosensitive coloring material and reversible thermosensitive recording material using the reversible thermosensitive coloring material | RICOH COMPANY LIMITED (JP) | 2008-09-02 | — | — | US | disclosed |
| US-20070259782-A1 | REVERSIBLE THERMOSENSITIVE COLORING MATERIAL AND REVERSIBLE THERMOSENSITIVE RECORDING MATERIAL USING THE REVERSIBLE THERMOSENSITIVE COLORING MATERIAL | RICOH COMPANY, LIMITED (JP) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283245-A1 | AZABICYCLO[3.1.0]HEX-2-YL COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AGER, AZI2, HTT | HPGD 1630/4885ALDH1A1 310/4885MAPT 52/4885 |
| US-20110136886-A1 | Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them | HRH2, HRH4, HRH3 | HPGD 666/4885ALDH1A1 427/4885MAPT 2026/4885 |
| US-20090312389-A1 | Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them | CHAT, MAOB, ALKBH2 | HPGD 3539/4885ALDH1A1 218/4885MAPT 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.